Diabetes researchers are studying a drug known as difluoromethylornithine (DFMO) that may reduce stress in cells that make insulin and preserve the body’s own insulin production.
The Tadpol Study is currently seeking participants who were diagnosed with Type 1 diabetes within the past 100 days. Researchers are trying to learn whether DFMO may be a useful treatment to improve beta cell health for persons with Type 1 diabetes.